GlassScriptPhysician profile
Casey Badik
NPI 1700305463
$1,744.10
in general payments reported to CMS, 2019-2025
21 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2023: $675 · 2024: $662 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $345.89 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $306.98 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $253.84 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $122.28 | 2021 | |
| Exact Sciences Corporation | $93.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $90.66 | 2023-2025 | |
| Shield Therapeutics INC | $77.31 | 2023-2024 | Accrufer |
| Sumitomo Pharma America, INC. | $66.93 | 2024-2025 | Gemtesa, Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.04 | 2023-2024 | Xifaxan |
| Pfizer INC. | $56.18 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $48.44 | 2023-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Lilly USA, LLC | $39.90 | 2024-2025 | Jardiance |
| Lundbeck LLC | $36.66 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $26.18 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.57 | 2023 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.46 | 2024 | Repatha, Otezla |
| Actelion Pharmaceuticals US, INC. | $19.63 | 2025 | Opsumit |
| Idorsia Pharmaceuticals US INC | $16.30 | 2023 | Quviviq |
| Verona Pharma, INC. | $15.57 | 2025 | Ohtuvayre |
| Nestle Healthcare Nutrition INC. | $14.05 | 2023 | |
| Aimmune Therapeutics, INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Badik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.